Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

CME Group Inc ha un prezzo obiettivo di consenso di $262.05 basato sulle valutazioni di 20 analisti. Il massimo è $314, pubblicato da Morgan Stanley il ottobre 23, 2025. Il minimo è $187, pubblicato da Rosenblatt il aprile 25, 2024. Le 3 valutazioni di analisti più recenti sono state pubblicate da Piper Sandler, UBS e Morgan Stanley il novembre 13, 2025, ottobre 23, 2025 e ottobre 23, 2025. Con un prezzo obiettivo medio di $302.33 tra Piper Sandler, UBS e Morgan Stanley, c’è una variazione implicita del 10.71% upside per CME Group Inc a partire da queste ultime valutazioni degli analisti.
1calcolato in base alle valutazioni degli analisti
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/13/2025 | 14.61% | Piper Sandler | $296 → $313 | Maintains | Overweight | |||
10/23/2025 | 2.53% | UBS | $285 → $280 | Maintains | Neutral | |||
10/23/2025 | 14.98% | Morgan Stanley | $312 → $314 | Maintains | Overweight | |||
10/23/2025 | 9.85% | Deutsche Bank | $266 → $300 | Upgrade | Hold → Buy | |||
10/13/2025 | 12.42% | Raymond James | $309 → $307 | Maintains | Outperform | |||
10/08/2025 | 2.53% | Barclays | $298 → $280 | Maintains | Equal-Weight | |||
10/01/2025 | 14.25% | Morgan Stanley | $303 → $312 | Maintains | Overweight | |||
09/25/2025 | -7.72% | JP Morgan | $246 → $252 | Maintains | Underweight | |||
09/25/2025 | 9.85% | Citigroup | $275 → $300 | Upgrade | Neutral → Buy | |||
09/08/2025 | 4.36% | UBS | $305 → $285 | Maintains | Neutral | |||
07/24/2025 | 11.68% | UBS | $305 → $305 | Downgrade | Buy → Neutral | |||
07/24/2025 | 10.95% | Oppenheimer | $300 → $303 | Maintains | Outperform | |||
07/24/2025 | 9.12% | Barclays | $299 → $298 | Maintains | Equal-Weight | |||
07/15/2025 | 8.39% | Piper Sandler | $283 → $296 | Maintains | Overweight | |||
07/10/2025 | 9.49% | Barclays | $283 → $299 | Maintains | Equal-Weight | |||
07/03/2025 | 0.7% | Citigroup | $265 → $275 | Maintains | Neutral | |||
06/04/2025 | 9.85% | Oppenheimer | $282 → $300 | Maintains | Outperform | |||
04/25/2025 | 11.68% | UBS | $290 → $305 | Maintains | Buy | |||
04/24/2025 | 3.26% | Oppenheimer | $279 → $282 | Maintains | Outperform | |||
04/24/2025 | 11.32% | Morgan Stanley | $301 → $304 | Maintains | Overweight | |||
04/24/2025 | -0.03% | Keefe, Bruyette & Woods | $265 → $273 | Maintains | Market Perform | |||
04/24/2025 | -22.74% | JP Morgan | $223 → $211 | Maintains | Underweight | |||
04/23/2025 | 3.63% | Barclays | $279 → $283 | Maintains | Equal-Weight | |||
04/11/2025 | 2.16% | Oppenheimer | $269 → $279 | Maintains | Outperform | |||
04/08/2025 | 10.22% | Morgan Stanley | $263 → $301 | Upgrade | Equal-Weight → Overweight | |||
04/08/2025 | 3.63% | Piper Sandler | $275 → $283 | Maintains | Overweight | |||
04/07/2025 | 2.16% | Barclays | $263 → $279 | Maintains | Equal-Weight | |||
04/03/2025 | -1.5% | RBC Capital | $269 → $269 | Reiterates | Sector Perform → Sector Perform | |||
04/02/2025 | -19.81% | B of A Securities | $200 → $219 | Maintains | Underperform | |||
03/10/2025 | 5.09% | Raymond James | → $287 | Upgrade | Market Perform → Outperform | |||
02/19/2025 | -3.69% | Morgan Stanley | $256 → $263 | Maintains | Equal-Weight | |||
02/14/2025 | -5.89% | Keefe, Bruyette & Woods | $256 → $257 | Maintains | Market Perform | |||
02/13/2025 | -1.5% | RBC Capital | $235 → $269 | Maintains | Sector Perform | |||
02/13/2025 | -1.5% | Oppenheimer | $258 → $269 | Maintains | Outperform | |||
02/13/2025 | -22.37% | JP Morgan | $209 → $212 | Maintains | Underweight | |||
02/13/2025 | -3.69% | Barclays | $257 → $263 | Maintains | Equal-Weight | |||
01/13/2025 | -6.26% | Keefe, Bruyette & Woods | $260 → $256 | Maintains | Market Perform | |||
01/07/2025 | -5.53% | Piper Sandler | $250 → $258 | Maintains | Overweight | |||
01/06/2025 | -13.95% | RBC Capital | $235 → $235 | Reiterates | Sector Perform → Sector Perform | |||
01/06/2025 | -8.46% | Citigroup | $255 → $250 | Downgrade | Buy → Neutral | |||
12/20/2024 | -4.79% | Keefe, Bruyette & Woods | $237 → $260 | Maintains | Market Perform | |||
12/09/2024 | -5.89% | Barclays | $231 → $257 | Maintains | Equal-Weight | |||
11/11/2024 | -17.24% | Deutsche Bank | $227 → $226 | Maintains | Hold | |||
10/28/2024 | -8.46% | Piper Sandler | $240 → $250 | Maintains | Overweight | |||
10/24/2024 | -13.95% | RBC Capital | $235 → $235 | Reiterates | Sector Perform → Sector Perform | |||
10/24/2024 | -5.53% | Oppenheimer | $245 → $258 | Maintains | Outperform | |||
10/24/2024 | -6.62% | Citigroup | $250 → $255 | Maintains | Buy | |||
10/24/2024 | -15.41% | Barclays | $219 → $231 | Maintains | Equal-Weight | |||
10/17/2024 | -14.68% | Morgan Stanley | $210 → $233 | Maintains | Equal-Weight | |||
10/14/2024 | -10.29% | Oppenheimer | $228 → $245 | Maintains | Outperform | |||
10/08/2024 | -10.65% | Redburn Atlantic | → $244 | Downgrade | Buy → Neutral | |||
10/08/2024 | -12.12% | Piper Sandler | $225 → $240 | Maintains | Overweight | |||
10/07/2024 | -19.81% | Barclays | $209 → $219 | Maintains | Equal-Weight | |||
10/03/2024 | -8.46% | Citigroup | $240 → $250 | Maintains | Buy | |||
10/03/2024 | -27.5% | Goldman Sachs | $195 → $198 | Maintains | Sell | |||
10/03/2024 | -13.95% | RBC Capital | $235 → $235 | Reiterates | Sector Perform → Sector Perform | |||
10/03/2024 | -34.09% | B of A Securities | $177 → $180 | Maintains | Underperform | |||
09/27/2024 | -13.95% | RBC Capital | → $235 | Initiates | → Sector Perform | |||
09/26/2024 | -19.07% | TD Cowen | → $221 | Initiates | → Hold | |||
09/03/2024 | -35.19% | B of A Securities | $212 → $177 | Downgrade | Neutral → Underperform | |||
08/20/2024 | -17.61% | Piper Sandler | $225 → $225 | Reiterates | Overweight → Overweight | |||
08/15/2024 | -26.76% | Deutsche Bank | $193 → $200 | Maintains | Hold | |||
07/25/2024 | -29.33% | Deutsche Bank | $195 → $193 | Maintains | Hold | |||
07/25/2024 | -30.06% | JP Morgan | $187 → $191 | Maintains | Underweight | |||
07/25/2024 | -22% | Keefe, Bruyette & Woods | $212 → $213 | Maintains | Market Perform | |||
07/25/2024 | -23.47% | Barclays | $208 → $209 | Maintains | Equal-Weight | |||
07/25/2024 | -17.61% | Piper Sandler | $235 → $225 | Maintains | Overweight | |||
07/10/2024 | -23.83% | Barclays | $228 → $208 | Maintains | Equal-Weight | |||
07/09/2024 | -13.95% | Piper Sandler | $250 → $235 | Maintains | Overweight | |||
07/03/2024 | -17.24% | Keefe, Bruyette & Woods | $226 → $226 | Maintains | Market Perform | |||
06/21/2024 | -31.52% | JP Morgan | $206 → $187 | Downgrade | Neutral → Underweight | |||
04/25/2024 | -16.51% | Barclays | $226 → $228 | Maintains | Equal-Weight | |||
04/25/2024 | -20.91% | B of A Securities | $209 → $216 | Maintains | Neutral | |||
04/25/2024 | -24.57% | JP Morgan | $198 → $206 | Maintains | Neutral | |||
04/25/2024 | -17.24% | Keefe, Bruyette & Woods | $222 → $226 | Maintains | Market Perform | |||
04/25/2024 | -31.52% | Rosenblatt | $185 → $187 | Reiterates | Sell → Sell | |||
04/09/2024 | -17.61% | Morgan Stanley | $222 → $225 | Maintains | Equal-Weight | |||
04/08/2024 | -17.24% | Barclays | $225 → $226 | Maintains | Equal-Weight | |||
04/05/2024 | -23.1% | Deutsche Bank | $235 → $210 | Downgrade | Buy → Hold | |||
04/03/2024 | -16.14% | Keefe, Bruyette & Woods | → $229 | Maintains | Market Perform | |||
03/06/2024 | -10.29% | Argus Research | $225 → $245 | Maintains | Buy | |||
02/15/2024 | -17.61% | Barclays | $222 → $225 | Maintains | Equal-Weight | |||
01/08/2024 | -18.71% | Barclays | $244 → $222 | Downgrade | Overweight → Equal-Weight | |||
01/04/2024 | -34.09% | Rosenblatt | → $180 | Reiterates | Sell → Sell | |||
01/03/2024 | -28.59% | Goldman Sachs | → $195 | Downgrade | Neutral → Sell | |||
10/26/2023 | -10.65% | Barclays | $247 → $244 | Maintains | Overweight | |||
10/26/2023 | -19.44% | Morgan Stanley | $215 → $220 | Maintains | Equal-Weight | |||
10/26/2023 | -34.09% | Rosenblatt | $173 → $180 | Maintains | Sell | |||
10/12/2023 | -12.12% | Citigroup | $215 → $240 | Maintains | Buy | |||
10/11/2023 | -27.86% | JP Morgan | $190 → $197 | Maintains | Neutral | |||
10/11/2023 | -21.27% | Morgan Stanley | $211 → $215 | Maintains | Equal-Weight | |||
10/11/2023 | -12.12% | Deutsche Bank | $224 → $240 | Maintains | Buy | |||
10/10/2023 | -9.55% | Barclays | $230 → $247 | Maintains | Overweight | |||
10/04/2023 | -36.65% | Rosenblatt | → $173 | Reiterates | Sell → Sell | |||
09/06/2023 | -25.3% | B of A Securities | $167 → $204 | Upgrade | Underperform → Neutral | |||
07/27/2023 | -15.78% | Barclays | $215 → $230 | Maintains | Overweight | |||
07/27/2023 | -26.76% | Keefe, Bruyette & Woods | $197 → $200 | Maintains | Market Perform | |||
07/27/2023 | -18.71% | Oppenheimer | → $222 | Reiterates | Outperform → Outperform | |||
07/27/2023 | -22.74% | Morgan Stanley | $210 → $211 | Maintains | Equal-Weight | |||
07/27/2023 | -21.27% | Citigroup | $210 → $215 | Maintains | Buy |
L'ultimo obiettivo di prezzo per CME Group (NASDAQ:CME) è stato riportato da {{analyst} in data {{date}}. La società di analisi ha fissato un obiettivo di prezzo per $313.00 prevedendo che CME raggiunga rise entro 12 mesi (un possibile 14.61% upside).
L'ultima valutazione degli analisti per CME Group (NASDAQ:CME) è stato fornita da Piper Sandler e CME Group mantenuto il suo rating overweight.
L'ultima revisione al rialzo di CME Group Inc è avvenuta il ottobre 23, 2025, quando Deutsche Bank ha alzato il suo obiettivo di prezzo a $300. In precedenza Deutsche Bank aveva a hold per CME Group Inc.
L'ultima revisione al ribasso di CME Group Inc si è verificata il luglio 24, 2025, quando UBS ha modificato il suo obiettivo di prezzo da $305 a $305 per CME Group Inc.
Gli analisti giungono alle valutazioni dei titoli dopo aver fatto ricerche approfondite, che comprendono l'esame dei bilanci pubblici, i colloqui con i dirigenti e i clienti di CME Group e l'ascolto delle comunicazioni degli utili. La maggior parte degli analisti svolge questa attività ogni tre mesi, quindi dovresti ricevere 4 valutazioni all'anno per azienda e per società. L'ultima valutazione di CME Group è stata depositata il novembre 13, 2025, quindi dovresti aspettarti che la prossima valutazione sia disponibile intorno a novembre 13, 2026.
Sebbene le valutazioni siano soggettive e possano cambiare, l'ultima valutazione di CME Group (CME) è stata una mantenuto con un obiettivo di prezzo di $296.00 a $313.00. Il prezzo attuale a cui CME Group (CME) è scambiato è $273.09, che è out of del range previsto dall'analista.
Sfoglia valutazioni degli analisti e obiettivi di prezzo su tutte le azioni.